Astria Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Glazer Capital, LLC and Paul J. Glazer have reported a 6.61% beneficial ownership stake in Astria Therapeutics, Inc. as of December 31, 2025.
Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 5.53% in Astria Therapeutics, Inc. common stock.
Vestal Point Capital, LP and Ryan Wilder have reported a shared beneficial ownership of 8.8% in Astria Therapeutics, Inc., totaling 4,956,000 shares.
Forbion Growth III PA B.V. and related entities report 0% beneficial ownership in Astria Therapeutics, Inc. common stock.
FMR LLC and Abigail P. Johnson report a 2.2% beneficial ownership of Astria Therapeutics Inc. common stock as of October 31, 2025.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued 9.1% beneficial ownership in Astria Therapeutics Inc. common stock.
SCHEDULE 13G/A: Millennium Entities Disclose Astria Therapeutics Stake
Millennium Management and affiliated entities have disclosed passive beneficial ownership in Astria Therapeutics, Inc. common stock.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC filed an Amendment No. 7 to Schedule 13G, reporting a 4.0% beneficial ownership in Astria Therapeutics, Inc. common stock.
RA Capital Management and its affiliates have fully divested their beneficial ownership in Astria Therapeutics, Inc. as of June 30, 2025.
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have collectively disclosed beneficial ownership of over 5% of Astria Therapeutics, Inc.'s common stock.
ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. have jointly disclosed a passive beneficial ownership of 6.8% in Astria Therapeutics, Inc.'s common stock.
FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 12.3% of Astria Therapeutics, Inc.'s Common Stock as of March 31, 2025.
SCHEDULE 13G/A: Venrock Healthcare Entities Maintain 4.4% Stake in Astria Therapeutics, Inc. as of Year-End 2024
A group of Venrock Healthcare entities and individuals have filed an amended Schedule 13G, confirming their collective beneficial ownership of 4.4% of Astria Therapeutics, Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G/A: Fairmount Funds Discloses 9.9% Stake in Astria Therapeutics, Inc. via Latest SEC Filing
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have reported a combined beneficial ownership of 9.9% in Astria Therapeutics, Inc., totaling 5,869,037 shares, including common stock and exercisable warrants.
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 13.9% Stake in Astria Therapeutics
FMR LLC and Abigail P. Johnson have disclosed a continued beneficial ownership of 13.9% in Astria Therapeutics, Inc. common stock as of December 31, 2024.
SCHEDULE 13G/A: Millennium Entities Amend Passive Stake in Astria Therapeutics, Reporting 3.5% Beneficial Ownership
Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing a 3.5% passive beneficial ownership stake in Astria Therapeutics, Inc. as of December 31, 2024.
ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. have jointly reported a 5.1% passive beneficial ownership stake in Astria Therapeutics, Inc.